CD8A and neoplasm: Combined anti-CD47 immunotherapy can synergistically inhibit tumor growth and recurrence by increasing the efficiency of tumor infiltration by M1 macrophages and cytotoxic CD3+ and CD8+ T cells while decreasing the efficiency of immunosuppressive regulatory T cells.